PT-141 vs Melanotan-2
How do PT-141 and Melanotan-2 compare for Muscle, IGF & Body Composition research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.
At a glance
PT-141
Melanotan-2
Which fits which research target?
Both PT-141 and Melanotan-2 sit within Muscle, IGF & Body Composition research but are studied for different primary signals. Neither is an approved medicine — compare the evidence, not marketing claims.
What the research shows
PT-141
FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Approval was based on trials showing improved satisfying sexual events and desire scores. Research in male sexual dysfunction shows pro-erectile effects via central pathways. Side effects include transient blood pressure increase and nausea.
Melanotan-2
Compare prices across EU suppliers
Compare PT-141 across EU suppliers
12 EU vendors · COA · from €22.63
Compare Melanotan-2 across EU suppliers
9 EU vendors · COA · from €29.9
Frequently asked questions
Is PT-141 or Melanotan-2 better? ▾
Neither is an approved medicine, and “better” depends on the research target. PT-141 is most associated with Muscle, IGF & Body Composition, while Melanotan-2 is studied for Melanogenesis & tanning. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.
Why compare PT-141 and Melanotan-2? ▾
Both are studied within Muscle, IGF & Body Composition research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.
Which is cheaper in the EU, PT-141 or Melanotan-2? ▾
Prices vary by supplier, vial size and COA status. PT-141 is listed from €22.63 across 12 COA-verified EU vendors; Melanotan-2 from €29.9 across 9. Open the price pages above to compare current listings — nobody pays us for placement.